Health System Readiness for Genomic Medicine in Oncology

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Palliative and Supportive Care".

Deadline for manuscript submissions: closed (15 February 2024) | Viewed by 6891

Special Issue Editors


E-Mail Website
Guest Editor
School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, ON, Canada
Interests: health economics; health policy; care organization

E-Mail Website
Guest Editor
William Osler Health System, Brampton, ON, Canada
Interests: personalized medicine; biomarker; pathology practice

E-Mail Website
Guest Editor
Department of Oncology, Queen’s University, Kingston, ON, Canada
Interests: cancer health services; access to cancer therapy; quality of cancer therapy; population-based phase IV trials of cancer therapy; global health and oncology; population-based models for cancer service planning

Special Issue Information

Dear Colleagues,

Demand for access to genome-based diagnostics (i.e., protein expression (e.g., immunohistochemical, proteomic); cytogenetic (e.g., karyotyping, fluorescent in situ hybridization, microarray); molecular (e.g., quantitative polymerase chain reaction [PCR], sequencing)) has increased in lockstep with the understanding of the genetic basis of disease. The increased need for testing may put considerable strain on healthcare systems and providers and lead to unwarranted delays and inequity of access to testing by geographic region.

The Aim of the Special Issue is to describe practical approaches to support healthcare system demand for genome-based diagnostics intended to improve experiences for patient and care providers, indicators of population health, and overall value for money. This could include a number of factors related to re-organization and implementation, including novel approaches to the following:

  • Health and human resource planning;
  • Care coordination;
  • Consideration of new technology for adoption or removal;
  • Health technology assessment;
  • Ongoing monitoring of quality and accreditation;
  • How data are shared, including changes to privacy legislation;
  • Integrating investigational, translational and mainstream healthcare delivery functions;
  • Financing and/or pricing and reimbursement of testing;
  • Integration of laboratory information systems;
  • Engagement and creating communities of practice;
  • Communicating new test information to patients and care providers“
  • "new approaches to old problems" techniquesfor example, Idylla

The aim of the Special Issue is to highlight new approaches intended to make health systems ready for the future of genomic medicine. It is intended to highlight the increasingly important role of the laboratory function and how this must evolve to be most beneficial to patients.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Scoping/systematic reviews and other knowledge syntheses;
  • Economic evaluations;
  • Quality improvement initiatives;
  • Narrative descriptions of current and future states of delivery;
  • Interventional studies (observational, RCTs).

We look forward to receiving your contributions.

Prof. Don R. Husereau
Dr. Brandon S. Sheffield
Dr. Timothy P. Hanna
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1080 KiB  
Article
Workforce Implications of Increased Referrals to Hereditary Cancer Services in Canada: A Scenario-Based Analysis
by Nick Dragojlovic, Kennedy Borle, Nicola Kopac, Amy Nisselle, Jennifer Nuk, Mandy Jevon, Jan M. Friedman, Alison M. Elliott and Larry D. Lynd
Curr. Oncol. 2023, 30(8), 7241-7251; https://doi.org/10.3390/curroncol30080525 - 29 Jul 2023
Viewed by 1666
Abstract
Over the last decade, utilization of clinical genetics services has grown rapidly, putting increasing pressure on the workforce available to deliver genetic healthcare. To highlight the policy challenges facing Canadian health systems, a needs-based workforce requirements model was developed to determine the number [...] Read more.
Over the last decade, utilization of clinical genetics services has grown rapidly, putting increasing pressure on the workforce available to deliver genetic healthcare. To highlight the policy challenges facing Canadian health systems, a needs-based workforce requirements model was developed to determine the number of Canadian patients in 2030 for whom an assessment of hereditary cancer risk would be indicated according to current standards and the numbers of genetic counsellors, clinical geneticists and other physicians with expertise in genetics needed to provide care under a diverse set of scenarios. Our model projects that by 2030, a total of 90 specialist physicians and 326 genetic counsellors (1.7-fold and 1.6-fold increases from 2020, respectively) will be required to provide Canadians with indicated hereditary cancer services if current growth trends and care models remain unchanged. However, if the expansion in eligibility for hereditary cancer assessment accelerates, the need for healthcare providers with expertise in genetics would increase dramatically unless alternative care models are widely adopted. Increasing capacity through service delivery innovation, as well as mainstreaming of cancer genetics care, will be critical to Canadian health systems’ ability to meet this challenge. Full article
(This article belongs to the Special Issue Health System Readiness for Genomic Medicine in Oncology)
Show Figures

Figure 1

16 pages, 549 KiB  
Article
Progress toward Health System Readiness for Genome-Based Testing in Canada
by Don Husereau, Eva Villalba, Vivek Muthu, Michael Mengel, Craig Ivany, Lotte Steuten, Daryl S. Spinner, Brandon Sheffield, Stephen Yip, Philip Jacobs, Terrence Sullivan and Larry Arshoff
Curr. Oncol. 2023, 30(6), 5379-5394; https://doi.org/10.3390/curroncol30060408 - 01 Jun 2023
Cited by 1 | Viewed by 2751
Abstract
(1) Background: Genomic medicine harbors the real potential to improve the health and healthcare journey of patients, care provider experiences, and improve the health system efficiency—even reducing healthcare costs. There is expected to be an exponential growth in medically necessary new genome-based tests [...] Read more.
(1) Background: Genomic medicine harbors the real potential to improve the health and healthcare journey of patients, care provider experiences, and improve the health system efficiency—even reducing healthcare costs. There is expected to be an exponential growth in medically necessary new genome-based tests and test approaches in the coming years. Testing can also create scientific research and commercial opportunities beyond healthcare decision making. The purpose of this research is to generate a better understanding of Canada’s state of readiness for genomic medicine, and to provide some insights for other healthcare systems. (2) Methods: A mixed-methods approach of a review of the literature and key informant interviews with a purposive sample of experts was used. The health system readiness was assessed using a previously published set of conditions. (3) Results: Canada has created some of the established conditions, but further action needs to be taken to improve the state of readiness for genome-based medicine. The important gaps to be filled are the need for linked information systems and data integration; evaluative processes that are timely and transparent; navigational tools for care providers; dedicated funding to facilitate rapid onboarding and support test development and proficiency testing; and broader engagement with innovation stakeholders beyond care providers and patients. These findings highlight the role of the organizational context, social influence, and other factors that are known to affect the diffusion of innovation within health systems. Full article
(This article belongs to the Special Issue Health System Readiness for Genomic Medicine in Oncology)
Show Figures

Figure 1

Review

Jump to: Research

10 pages, 251 KiB  
Review
Future Role of Health Technology Assessment for Genomic Medicine in Oncology: A Canadian Laboratory Perspective
by Don Husereau, Yvonne Bombard, Tracy Stockley, Michael Carter, Scott Davey, Diana Lemaire, Erik Nohr, Paul Park, Alan Spatz, Christine Williams, Aaron Pollett, Bryan Lo, Stephen Yip, Soufiane El Hallani and Harriet Feilotter
Curr. Oncol. 2023, 30(11), 9660-9669; https://doi.org/10.3390/curroncol30110700 - 31 Oct 2023
Viewed by 1399
Abstract
Genome-based testing in oncology is a rapidly expanding area of health care that is the basis of the emerging area of precision medicine. The efficient and considered adoption of novel genomic medicine testing is hampered in Canada by the fragmented nature of health [...] Read more.
Genome-based testing in oncology is a rapidly expanding area of health care that is the basis of the emerging area of precision medicine. The efficient and considered adoption of novel genomic medicine testing is hampered in Canada by the fragmented nature of health care oversight as well as by lack of clear and transparent processes to support rapid evaluation, assessment, and implementation of genomic tests. This article provides an overview of some key barriers and proposes approaches to addressing these challenges as a potential pathway to developing a national approach to genomic medicine in oncology. Full article
(This article belongs to the Special Issue Health System Readiness for Genomic Medicine in Oncology)
Back to TopTop